• Eden Moore, Barbara G Silverman, Yehudit Fishler, Etty Ben-Adiva, Olga Davidov, Rita Dichtiar, Hila Edri, Miriam Zatlawi, and Lital Keinan-Boker.
• School of Public Health, University of California at Berkeley, Berkeley, CA, USA.
• Isr Med Assoc J. 2021 Jan 1; 23 (1): 23-27.

BackgroundThe Israel National Cancer Registry (INCR) was established in 1960. Reporting has been mandatory since 1982. All neoplasms of uncertain/unknown behavior, in situ and invasive malignancies (excluding basal and squamous cell carcinomas of the skin), and benign neoplasms of the brain and central nervous system (CNS) are reportable.ObjectivesTo assess completeness and timeliness of the INCR for cases diagnosed or treated in 2005.MethodsAbstractors identified cases of in situ and invasive malignancies and tumors of benign and uncertain behavior of the brain and CNS diagnosed or treated in 2005 in the files of medical records departments, pathology and cytology laboratories, and oncology and hematology institutes in 39 Israeli medical facilities. Cases were linked to the INCR database by national identity number. Duplicate cases, and those found to be non-reportable were excluded from analysis. Completeness was calculated as the percent of reportable cases identified by the survey that were present in the registry. Timeliness was calculated as the percent of reportable cases diagnosed in 2005, which were incorporated into the registry prior to 31 December 2007.ResultsThe INCR's completeness is estimated at 93.7% for all reportable diseases, 96.8% for invasive solid tumors, and 88.0% for hematopoietic tumors. Incident cases for the calendar year 2005 were less likely to be present in the registry database than those diagnosed prior to 2005.ConclusionsCompleteness and timeliness of the INCR are high and meet international guidelines. Fully automated reporting will likely improve the quality and timeliness of INCR data.

17 keywords...

hide…